Literature DB >> 11285382

Minocycline-induced lupus: clinical features and response to rechallenge.

T M Lawson1, N Amos, D Bulgen, B D Williams.   

Abstract

OBJECTIVE: To describe the spectrum of clinical features in patients with minocycline-induced lupus (MIL) and determine their response to rechallenge.
METHODS: The clinical features and laboratory findings of 23 patients with MIL were recorded. Ten patients were rechallenged, and their C-reactive protein (CRP) levels were monitored.
RESULTS: All subjects complained of polyarthralgia; three had metacarpophalangeal and proximal interphalangeal joint synovitis and one had bilateral knee effusions. Elevated hepatic transaminases were noted in eight subjects. Cutaneous vasculitis was a feature in two cases. None had renal or central nervous system disease, although five patients complained of impaired concentration and poor memory and a single patient had a peripheral sensory neuropathy. The following serological abnormalities were detected: antinuclear antibodies (19/23 patients); antibodies to double-stranded DNA (4/23); perinuclear antineutrophil cytoplasmic antibodies (10/15); IgG anti-cardiolipin antibodies (6/23); hypergammaglobulinaemia (12/19). Anti-histone antibodies were negative in 9/9 cases. Rechallenge resulted in rapid recurrence of symptoms and elevation of CRP levels.
CONCLUSION: MIL is associated with a wide spectrum of clinical and serological features. The diagnosis can be confirmed by rechallenge, which results in rapid reappearance of symptoms and a rise in CRP.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11285382     DOI: 10.1093/rheumatology/40.3.329

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  14 in total

Review 1.  Drug-induced lupus erythematosus: incidence, management and prevention.

Authors:  Christopher Chang; M Eric Gershwin
Journal:  Drug Saf       Date:  2011-05-01       Impact factor: 5.606

2.  "Lupoid hepatitis" in SLE patients and mice with experimental lupus.

Authors:  Stepan Shumyak; Li-Jun Yang; Shuhong Han; Haoyang Zhuang; Westley H Reeves
Journal:  Clin Immunol       Date:  2016-07-16       Impact factor: 3.969

3.  Side effects of minocycline treatment in patients with fragile X syndrome and exploration of outcome measures.

Authors:  Agustini Utari; Weerasak Chonchaiya; Susan M Rivera; Andrea Schneider; Randi J Hagerman; Sultana M H Faradz; Iryna M Ethell; Danh V Nguyen
Journal:  Am J Intellect Dev Disabil       Date:  2010-09

Review 4.  The importance of NAD in multiple sclerosis.

Authors:  W Todd Penberthy; Ikuo Tsunoda
Journal:  Curr Pharm Des       Date:  2009       Impact factor: 3.116

5.  Comprehensive behavioral testing in the R6/2 mouse model of Huntington's disease shows no benefit from CoQ10 or minocycline.

Authors:  Liliana B Menalled; Monica Patry; Natalie Ragland; Phillip A S Lowden; Jennifer Goodman; Jennie Minnich; Benjamin Zahasky; Larry Park; Janet Leeds; David Howland; Ethan Signer; Allan J Tobin; Daniela Brunner
Journal:  PLoS One       Date:  2010-03-22       Impact factor: 3.240

Review 6.  ANA (+) ANCA (+) systemic vasculitis associated with the use of minocycline: case-based review.

Authors:  Petar Lenert; Michael Icardi; Laila Dahmoush
Journal:  Clin Rheumatol       Date:  2013-04-21       Impact factor: 2.980

Review 7.  Mechanisms of immune-mediated liver injury.

Authors:  David H Adams; Cynthia Ju; Shashi K Ramaiah; Jack Uetrecht; Hartmut Jaeschke
Journal:  Toxicol Sci       Date:  2010-01-13       Impact factor: 4.849

8.  Long-lasting effects of minocycline on behavior in young but not adult Fragile X mice.

Authors:  L E Dansie; K Phommahaxay; A G Okusanya; J Uwadia; M Huang; S E Rotschafer; K A Razak; D W Ethell; I M Ethell
Journal:  Neuroscience       Date:  2013-05-07       Impact factor: 3.590

9.  Gut Microbiota in Human Systemic Lupus Erythematosus and a Mouse Model of Lupus.

Authors:  Xin M Luo; Michael R Edwards; Qinghui Mu; Yang Yu; Miranda D Vieson; Christopher M Reilly; S Ansar Ahmed; Adegbenga A Bankole
Journal:  Appl Environ Microbiol       Date:  2018-01-31       Impact factor: 4.792

10.  Subacute neuronopathy in a young man: a possible association with tetracycline treatment.

Authors:  Magnus Vrethem; Charlotte Dahle; Björn Lindvall
Journal:  Neurol Int       Date:  2011-11-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.